Comparative Hepatoprotective Effects of Dapagliflozin and Silymarin Against Cyclophosphamide-Induced Liver Injury in Rats: Involvement of Nrf2/HO-1, HNF4α, and HNF6 Pathways

Authors

  • Afrah Thiab Hlail Department of Pharmacology and Toxicology, College of Pharmacy, Thi-Qar University , Thi-Qar, Iraq
  • Nada Naji Al-Shawi Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq

DOI:

https://doi.org/10.31351/vol35iss2pp155-165

Abstract

Background: Cyclophosphamide (Cpd), a common immunosuppressive and chemotherapeutic drug, can cause hepatotoxicity by inducing inflammation and oxidative stress. Dapagliflozin (Dapa) and other sodium-glucose cotransporter-2 inhibitors (SGLT2i) have anti-inflammatory and antioxidant properties, and Silymarin is a natural compound extracted from the seeds of the milk thistle plant (Silybum marianum). It is best known for its antioxidant, anti-inflammatory, and hepatoprotective effects.Objective: By measuring oxidative stress, inflammation, and liver regeneration parameters, with an emphasis on the Nrf2/HO-1 pathway and hepatocyte nuclear factors (HNF4α and HNF6), Dapa's hepatoprotective effects in comparison to Sil on Cpd-induced liver injury will be evaluated. Methods: Five (5) groups of male rats ten rats each were created: control, vehicle (Na-CMC), Cpd (30mg/kg), Cpd + Dapa (3mg/kg), and Cpd + Sil (200mg/kg).. Rat liver tissue was examined for Nrf2, HO-1 (qRT-PCR), HNF4α (ELISA), and HNF6 (Western blot) levels after ten days. Results: Cpd significantly reduced Nrf2, HO-1, HNF4α, and HNF6 levels (*p < 0.0001). Dapa and Sil restored these markers, with Dapa showing superior upregulation of Nrf2 (2.182 ± 0.540 vs. Cpd 0.244 ± 0.096) and HO-1 (2.051 ± 0.533 vs. CP 0.487 ± 0.178) (*p< 0.0001). Dapa also significantly increased HNF4α (2135 ± 297.9 vs. CP 229.5 ± 50.21) and HNF6 (3.635 ± 0.610 vs. CP 0.515 ± 0.255) (*p< 0.001), outperforming Sil in enhancing HNF6 (*p < 0.05). Conclusion: Dapa ameliorates Cpd-induced hepatotoxicity by activating the Nrf2/HO-1 pathway and restoring HNF4α/HNF6 expression, demonstrating comparable or superior efficacy to Sil. These findings highlight Dapa’s potential as an adjunct therapy to mitigate chemotherapy-induced hepatotoxicity

How to Cite

1.
Afrah Thiab Hlail, Nada Naji Al-Shawi. Comparative Hepatoprotective Effects of Dapagliflozin and Silymarin Against Cyclophosphamide-Induced Liver Injury in Rats: Involvement of Nrf2/HO-1, HNF4α, and HNF6 Pathways. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2026 Jun. 24 [cited 2026 Jun. 25];35(2):155-6. Available from: https://www.bijps.uobaghdad.edu.iq/index.php/bijps/article/view/4673

Publication Dates

Received

2025-06-03

Revised

2025-06-12

Accepted

2025-11-28

Published Online First

2026-06-24

References

Highley MS, Landuyt B, Prenen H, Harper PG, Dicato M, Eisenhauer EA. The nitrogen mustards. Pharmacol Rev. 2022;74(3):552–599. https://doi: 10.1124/pharmrev.120.000121

Zalzala MH, Safar SK. The safranal effect against cyclophosphamide-induced liver injury. Iraqi J Pharm Sci. 2021;30(2):208–213.https://doi: 10.31351/vol30iss2pp208-213

Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Cyclophosphamide for the treatment of systemic lupus erythematosus. N Engl J Med. 2001;344(19):1423–1431. https://doi: 10.1056/NEJM200105103441903

van Vollenhoven RF, Bingham CO 3rd, Durez P, Smolen JS, Tak PP, van der Heijde D, et al. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2013;(6):CD001157. https://doi: 10.1002/14651858.CD001157.pub2

Jeelani R, Khan SN, Shaeib F, Kohan-Ghadr HR, Aldhaheri SR, Thakur M, et al. Cyclophosphamide and acrolein induced oxidative stress leading to deterioration of metaphase II mouse oocyte quality. Free Radic Biol Med. 2017;110:11–18. https://doi: 10.1016/j.freeradbiomed.2017.05.006

Kachur E, Patel JN, Morse AL, Moore DC, Arnall JR. Post-transplant cyclophosphamide for the prevention of graft-versus-host disease in allogeneic hematopoietic cell transplantation: A guide to management for the advanced practitioner. J Adv Pract Oncol. 2023;14(6):520–532. https://doi: 10.6004/ jadpro.2023.14.6.5

Maleki R, Noorbakhsh MF, Kazemipour N, Masoudian M, Namazi F, Nourian S. The hepatoprotective effects of sitagliptin against cyclophosphamide-induced hepatotoxicity in rats. Mol Biol Res Commun. 2024;13(4):193–200. https://doi: 10.22099/ mbrc. 2024. 49925 . 1964.

Althunibat OY, Abukhalil MH, Jghef MM, Alfwuaires MA, Algefare AI, Alsuwayt B, et al. Hepatoprotective effect of taxifolin on cyclophosphamide-induced oxidative stress, inflammation, and apoptosis in mice: Involvement of Nrf2/HO-1 signaling. Biomol Biomed. 2023;23(4):649–660. https://doi: 10.17305/bb.2022.8743

Dabbish E, Scoditti S, Shehata MNI, Ritacco I, Ibrahim MAA, Shoeib T, et al. Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study. J Comput Chem. 2024;45(10):663–670. https://doi: 10.1002/jcc.27280

Diana A, Averill-Bates AT. Activation of cellular signalling pathways and apoptosis by the aldehyde acrolein – A major environmental hazard. Redox Biochem Chem. 2024;7(4):1194–1201. https://doi: 10.1016/j.redox.2024.1194

Hawi AJ, Al-Shawi NN. Evaluation of the effect of fisetin against cyclophosphamide-induced myelosuppression and oxidative stress in male albino rats. Iraqi J Pharm Sci. 2023;32(2):120–127. https://doi: 10.31351/vol32iss2pp120-127

Ibrahim KM, Darwish SF, Mantawy EM, El-Demerdash E. Molecular mechanisms underlying cyclophosphamide-induced cognitive impairment and strategies for neuroprotection in preclinical models. Mol Cell Biochem. 2024 Aug;479(8):1873-1893. https://doi: 10.1007/s11010-023-04805-0.

Fender AC, Dobrev D. Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(18):589–592. https://doi: 10.1007/s00210-023-02456-7

Cheong AJY, Teo YN, Teo YH, Syn NL, Ong HT, Ting AZH, et al. SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials. Obesity (Silver Spring). 2022;30(1):117–128. https:// doi: 10.1002/oby.23345

Arab HH, Althobaiti MM, Alharthi AS, Almalki EO, Alsoubie SS, Qattan JM, et al. Repurposing dapagliflozin for mitigation of the kidney injury triggered by cadmium in rats: role of autophagy, apoptosis, and the SIRT1/Nrf2/HO‑1 pathway. Pharmaceuticals (Basel). 2024;17(12):1690. https://doi: 10.3390/ph17121690

Hassan NH, Kamel GM, Fayed HM, Korany RMS, Ramadan A. Dapagliflozin alleviates thioacetamide induced-liver fibrosis in rats via controlling the Nrf2/HO-1 and TLR4/TGF-β1/PI3K signaling pathways. Immuno-pharmacol Immunotoxicol. 2025 Jun;47(3):392-405. https://doi: 10.3390/ ph16071006

Al-Shawi NN, Saad Abdel-Rehman Hussain, Husam Hasson Ali, Yahia Zaki Rashid and Nawfal Abdel-munim Numan. Dose-dependent protective effects of silymarin against CCU-induced liver damage in rats. J Fac Med Baghdad. 2005;47(3):282–285. https://doi: 10. 32007/jfmb.v47i3.2005.282

Wla NJ, Naqishbandi AM. Preventive and therapeutic effects of Silybum marianum seed extract rich in silydianin and silychristin in a rat model of metabolic syndrome. ACS Pharmacol Transl Sci. 2023;6(11):1715–1723. https://doi: 10.1021/acsptsci.3c00171

Jaffar HM, Al‑Asmari F, Khan FA, Abdul Rahim M, Zongo E. Silymarin: unveiling its pharmacological spectrum and therapeutic potential in liver diseases—a comprehensive narrative review. Food Sci Nutr. 2024; 12(5):3097–3111. https://doi: 10.1002 /fsn3 . 4010

Atshan DA, Zalzala MH. Papaverine attenuates the progression of alphanaphthyliso-thiocyanate-induced cholestasis in rats. Curr Res Pharmacol Drug Discov. 2024 ;6: 100193. https://doi: 10.1016 /j.crphar .2024. 100193

Xu J, Yang Z, Zalzala M, Munaf M, Li Y, Zhang Y. Abstract 248: Hepatocyte nuclear factor 4α regulates lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(Suppl_1):248. https://doi:10.1161/atvb.34.suppl_1.248

Zhang Y, Hu J, Ci X. Amentoflavone protects against cisplatin-induced acute kidney injury by modulating Nrf2-mediated oxidative stress and ferroptosis and partially by activating Nrf2-dependent PANoptosis. Front Pharmacol. 2025;16:1508047. https://doi:10.3389/fphar.2025.1508047

Lin DW, Hsu YC, Chang CC, Hsieh CC. Insights into the molecular mechanisms of NRF2 in kidney injury and diseases. Int J Mol Sci. 2023;24(7):6053. https://doi:10.3390/ijms24076053

Tian M, Gao W, Ma S, Cao H, Zhang Y, An F, et al. Role of HNF6 in liver homeostasis and pathophysiology. Mol Med. 2025;31:48. https://doi:10.1186/s10020-025-00652-3

Qiu S, Pan Y, Cui Y, Li M, Yue T, Pu S, Zhang Q, et al. HNF4α improves hepatocyte regeneration by upregulating PXR. FASEB J. 2024;38(14):1346–52. https:// doi:10. 1096/fj.2 02400123R

Kotulkar M, Robarts DR. HNF4α in hepatocyte health and disease. Semin Liver Dis. 2023;43(2):234–44. https://doi:10.1055/a-2097-0660

Radi SH, Vemuri K, Martinez-Lomeli J, Sladek FM. HNF4α isoforms: the fraternal twin master regulators of liver function. Front Endocrinol (Lausanne). 2023;14:1226173. https://doi: 10. 3389 /fendo.2023.1226173

Vemuri K, Radi SH, Sladek FM. Multiple roles and regulatory mechanisms of the transcription factor HNF4 in the intestine. Front Endocrinol (Lausanne). 2023;14:1232569. https://doi:10.3389/fendo.2023.1232569

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555–77. https://doi:10.1038/sj.bjc.6605642

Hamm TE. Proposed institutional animal care and use committee guidelines for death as an endpoint in rodent studies. Contemp Top Lab Anim Sci. 1995;34(5):69–71.

Isa AS, Muhammad MS, Hudu AA, Jamba BI, Magaji MG. Hepatotoxic evaluation of carboxymethylcellulose in adult Wistar rats. J Med Bas Sci Res. 2022;3(2):33–40. https://doi:10.5281/zenodo.6457945 researchgate.net

Patwa J, Khan S, … GJ [surname missing]. Nicotinamide attenuates cyclophosphamide-induced hepatotoxicity in SD rats by reducing oxidative stress and apoptosis. J Biochem Mol Toxicol. 2020;34(10):2178–2188. doi:10.1002/jbt.21788

Fang L, Zhang C, Zhang M, et al. Dapagliflozin attenuates oxidative stress and inflammation in rats via Nrf2/HO‑1 pathway. Biomed Pharmacother. 2023;(161):114367-114378. https://doi:10.1016/j.biopha.2023.114367

Said WM Ahmed, Soliman A, Ahmed Amer AE, el‑Shahat RM, Amin MM, et al. Effect of dapagliflozin against NAFLD and dyslipidemia in type 2 diabetic albino rats: possible underlying mechanisms. Eur Rev Med Pharmacol Sci. 2023;27(17):8101–8109. https://doi:10.26355/eurrev_202309_33570 ouci.dntb.gov.ua europeanreview.org

El-Deib KM, Ahmed MM, Ahmed NZ. Biochemical evaluation of the protective impact of silymarin against cyclophosphamide‑induced hepatotoxicity in rats. Egypt J Biochem Mol Biol. 2011;29(2):147–155.

Wang T, Wang N, Liu X, Liu D, Liu Y, Xu X, et al. Silymarin prevents triptolide-induced acute hepatotoxicity via regulation of oxidative stress and apoptosis. Mol Med Rep. 2017;16(2):1477–1484. https://doi:10.3892/mmr.2017.7958

Atshan DA, Zalzala MH. Possible protective effect of papaverine on ANIT-induced cholestasis in rats. Iraqi J Pharm Sci. 2023;32(Suppl.):118–126. https://doi:10.31351/vol32issSuppl.pp118-126

D Meydan, B Gursel, B Bilgici, B Can, N Ozbek. Protective effect of lycopene against radiation‑induced hepatotoxicity in rats. J Int Med Res. 2011;39(4):1239-52. doi: 10.1177/ 1473 23001103900412.

Mohammed TA, Zalzala MH. Novel insights into bexarotene’s role in preventing cholestasis: mechanisms and implications. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(2):123–134. https:// doi:10. 1007/ s00 210 -025-03917-2

Kim TH, Mars WM, Stolz DB, Michalopoulos GK. Expression and function of hepatocyte nuclear factor-4α in rat liver regeneration. Am J Physiol Gastrointest Liver Physiol. 2005;289(5):G794–G802. https://doi: 10. 1152/ajpgi.00170.2005

Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43(4):244–58. https://doi.org /10.1093/ ilar.43.4.244

Al-Amarat W, Abukhalil MH, Alruhaimi RS, Alqhtani HA, Aldawood N, Alfwuaires MA, et al. Upregulation of Nrf2/HO-1 signaling and attenuation of oxidative stress, inflammation, and cell death mediate the protective effect of apigenin against cyclophosphamide hepatotoxicity. Metabolites. 2022;12(7):648-655 https://doi.org/10.3390/metabo12070648

Zhang X, Dong Z, Fan H, Yang Q, Yu G, Pan E, et al. Scutellarin prevents acute alcohol-induced liver injury via inhibiting oxidative stress by regulating the Nrf2/HO-1 pathway and inhibiting inflammation by regulating the AKT, p38 MAPK/NF-κB pathways. J Zhejiang Univ Sci B. 2023;24(7):617–31. https: // doi . org /10. 1631/jzus.B2200612

Phongphithakchai A, Tedasen A, Netphakdee R, Leelawattana R, Srithongkul T, Raksasuk S, et al. Dapagliflozin in chronic kidney disease: insights from network pharmacology and molecular docking simulation. Life (Basel). 2025;15(3):437-448. https://doi.org /10. 3390 /life15030437

Zhang J, Chen X, Lv S, Hu Q. Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2/HO-1/GPX4 signaling pathway. PLoS One. 2025;20(1):13-22 e0317295. https:// doi. org/ 10. 1371 /journal .pone .0317295

Satyam SM, Bairy LK, Rehman A, Attia M, Ahmed L, Emad K, et al. Unlocking synergistic hepatoprotection: dapagliflozin and silymarin combination therapy modulates nuclear erythroid 2-related factor 2/heme oxygenase-1 pathway in carbon tetrachloride-induced hepatotoxicity in Wistar rats. Biology (Basel). 2024;13(7):473-488. https:// doi. org/ 10. 3390/ biology13070473

Hassan HA, Nageeb MM, Mohammed HO, Samy W, Fawzy A, Afifi R, et al. Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis. Toxicol Appl Pharmacol. 2024;(302):116991-117001. https://doi.org/10.1016/j.taap.2024.116991

Belosludtseva NV, Starinets VS, Belosludtsev KN. Effect of Dapagliflozin on the Functioning of Rat Liver Mitochondria In Vitro. Bull Exp Biol Med. 2021 Sep;171(5):601-5. doi: 10.1007/s10517-021-05277-2.

Vargas-Mendoza N, Morales-González Á, Morales-Martínez M, Soriano-Ursúa MA, Delgado-Olivares L, Sandoval-Gallegos EM, et al. Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications. Biomedicines. 2020 May 14;8(5):122. doi: 10.3390/biomedicines8050122.

Li Y, Li H, Sun M, Chen H, Xiao Y, Wang J, et al. Silibinin alleviates acute liver failure by modulating AKT/GSK3β/Nrf2/GPX4 pathway. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):7625-39. doi: 10.1007/s00210-024-03760-x

Wang Y, Fu X, Zeng L, Hu Y, Gao R, Xian S, et al. Activation of Nrf2/HO-1 signaling pathway exacerbates cholestatic liver injury. Commun Biol. 2024;7(1):621-630. https://doi.org/10.1038/s42003-024-05830-1

Van Dender C, Vandewalle J, Cederlund CL. Balancing metabolism and regeneration in liver diseases through HNF4α targeting. Trends Endocrinol Metab. 2025;16(2):365–75. https://doi.org/10.1016/j.tem.2024.11.005

Kotulkar M, Paine-Cabrera D, Abernathy S, Robarts DR, Parkes WS, Lin-Rahardja K, et al. Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury. Hepatology. 2023;78(4):1106–17. https://doi.org/10.1002/hep.32864

Bica IC, Stoica RA, Salmen T, Janež A, Volčanšek Š, Popovic D, et al. The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: a systematic review of randomized controlled trials. Medicina (Kaunas). 2023; 59(6) :1136. doi: 10. 3390 /medicina59061136

Tian M, Gao W, Ma S, Liu J, Zhou C, Yang Y, et al. Role of HNF6 in liver homeostasis and pathophysiology. Mol Med. 2025;31(48):2123–9. doi:10.1186/s10020-025-01105-9

Wang MC, Zheng GD. Transcriptional activation by growth hormone of HNF-6-regulated hepatic genes, a potential mechanism for improved liver repair during biliary injury in mice. Am J Physiol Gastrointest Liver Physiol. 2018;295(2):G364–72. doi: 10. 1152 /ajpgi .00581 .2007

Sahu AA, Mukherjee A, Nirala SK, Bhadauria M. Cyclophosphamide-induced multiple organ dysfunctions: unravelling of dose dependent toxic impact on biochemistry and histology. Toxicol Res. 2024;13(6):tfae201. doi: 10. 1093 /toxres/tfae201

Sohail I, Malkani N, Tahir N, Khalil A, Attar RMS. Silymarin protects the liver from α-naphthylisothiocyanate-induced cholestasis by modulating the expression of genes involved in bile acid homeostasis. Cell Mol Biol (Noisy-le-grand). 2023;31(68):208–12. doi:10. 14715 /cmb/2023.68.7.33

Zhao DM, Li CQ, Sun YM, Fan JY, Wu N, Sun YN, et al. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice. Endokrynol Pol. 2023;27(2):190–6. doi: 10. 5603/EP.a2023.0018

Jin Z, Yin R, Yuan Y, Zheng C, Zhang P, Wang Y, et al. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids. Biochem Pharmacol. 2024;233:116167. doi: 10. 1016 /j.bcp .2024.116167

Wang X, Jin Y, Di C, Zeng Y, Zhou Y, Chen Y, et al. Supplementation of silymarin alone or in combination with salvianolic acids B and puerarin regulates gut microbiota and its metabolism to improve high-fat diet-induced NAFLD in mice. Nutrients. 2024;16(8):1478–86. doi:10.3390/nu16081478

Gonzalez FJ, Yu AM, Jiang Y, Fang J. Hepatocyte nuclear factor 4α is a central regulator of bile acid conjugation. J Biol Chem. 2004;279(4):2480–9. doi: 10. 1074 /jbc. M309377200

Chiang JY. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin Drug Metab Toxicol. 2009;5(2):137–47. doi: 10. 1517 /174 25 250 90 3473259

Downloads

Published

2026-06-24

Issue

Vol. 35 No. 2 (2026): Iraqi J Pharm Sci

Section

Article

Categories

License

Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.